Printer Friendly

CYTOGEN REPORTS FAVORABLE REPEAT ADMINISTRATION RESULTS IN COLORECTAL CANCER IMAGING

 PRINCETON, N.J., June 8 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) reported clinical data which showed that repeated infusions of OncoScint(R) Colorectal, a monoclonal antibody-based cancer imaging agent, may be safely performed and are clinically useful in the detection of recurrent colorectal cancer.
 At the 40th Annual Meeting of the Society of Nuclear Medicine in Toronto, Canada, Dr. Hani A. Nabi of the State University of New York at Buffalo, presented clinical trial results in which OncoScint Colorectal was repeatedly administered to 95 patients, with some patients receiving four or more infusions. In this multicenter study, OncoScint Colorectal was able to detect malignant lesions in 30 of 38 patients with confirmed disease (sensitivity = 79 percent). The presence of human antimouse antibody (HAMA), detected in 34 percent of patients, was associated with substantially faster OncoScint clearance than observed in the patients without HAMA. The effect of rapid clearance on imaging efficacy is not clear from this investigation.
 Nabi stated, "These results indicate that repeat administration of OncoScint Colorectal is well-tolerated and is able to provide the clinician with useful information regarding the presence, location, and extent of disease in the majority of colorectal cancer patients." He continued, "Statistically, the overall sensitivity and adverse effect rate (2.1 percent) upon repeat infusion in this study were virtually identical to the sensitivity and adverse effect rate seen in earlier studies involving only single infusions of OncoScint."
 On Dec. 29, 1992, OncoScint Colorectal was approved by the FDA for the imaging of extrahepatic malignant disease in patients with known colorectal cancer. This approval was based on patients who received a single dose. In October 1992, Cytogen filed supplemental data with the FDA to expand the original approved indication to include repeat administration and is awaiting FDA action.
 Cytogen is a biopharmaceutical company engaged in the development of products for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. Cytogen uses its patented and proprietary "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 /delval/
 -0- 6/8/93
 /CONTACT: Mary Beals, director of corporate communications of Cytogen, 609-987-8221/
 (CYTO)


CO: Cytogen Corporation ST: New Jersey IN: MTC SU:

MP -- PH009 -- 6432 06/08/93 10:04 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 8, 1993
Words:371
Previous Article:AEL WINS $2 MILLION AWARD
Next Article:SUSQUEHANNA NO. 142 MAKES TRACKS INTO NORH?ERN NEW JERSEY; NYS&W RAILWAY UNVEILS 1993 STEAM TRAIN RIDE SCHEDULE
Topics:


Related Articles
FDA APPROVES CYTOGEN PRODUCT AS FIRST MAB-BASED CANCER IMAGING AGENT IN THE UNITED STATES
CYTOGEN ANNOUNCES FIRST SHIPMENT OF ONCOSCINT CR/OV
CYTOGEN ANNOUNCES SATISFACTION WITH PRODUCT LAUNCH
CYTOGEN SCIENTISTS HONORED BY R&D COUNCIL OF NEW JERSEY
ONCOSCINT(R) CR103 REPEAT ADMINISTRATION AMENDMENT RECOMMENDED FOR APPROVAL IN EUROPE
CYTOGEN CORPORATION ANNOUNCES FOURTH QUARTER AND ANNUAL RESULTS
CYTOGEN CORPORATION ANNOUNCES UPDATE ON FIRST QUARTER ACHIEVEMENTS AND FINANCIAL RESULTS
CYTOGEN Submits ProstaScint(R) for Canadian Market Approval; ProstaScint(R) And OncoScint(R) Featured in Recent Publications and Presentations.
Cytogen Updates on Product Marketing Rights in Canada.
CYTOGEN Updates on Recent ProstaScint(R) Studies.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters